CL2015001049A1 - Terapia de combinación de anticuerpos anti-her3 - Google Patents
Terapia de combinación de anticuerpos anti-her3Info
- Publication number
- CL2015001049A1 CL2015001049A1 CL2015001049A CL2015001049A CL2015001049A1 CL 2015001049 A1 CL2015001049 A1 CL 2015001049A1 CL 2015001049 A CL2015001049 A CL 2015001049A CL 2015001049 A CL2015001049 A CL 2015001049A CL 2015001049 A1 CL2015001049 A1 CL 2015001049A1
- Authority
- CL
- Chile
- Prior art keywords
- combination therapy
- her3 antibody
- antibody combination
- her3
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151076 | 2013-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001049A1 true CL2015001049A1 (es) | 2015-10-16 |
Family
ID=47504772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001049A CL2015001049A1 (es) | 2013-01-11 | 2015-04-23 | Terapia de combinación de anticuerpos anti-her3 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9180185B2 (es) |
| EP (1) | EP2943508B1 (es) |
| JP (1) | JP6257646B2 (es) |
| KR (1) | KR20150093231A (es) |
| CN (1) | CN104797602A (es) |
| AR (1) | AR094403A1 (es) |
| AU (1) | AU2014204795A1 (es) |
| CA (1) | CA2887508A1 (es) |
| CL (1) | CL2015001049A1 (es) |
| CR (1) | CR20150284A (es) |
| EA (1) | EA201500744A1 (es) |
| HK (1) | HK1211950A1 (es) |
| IL (1) | IL238393A0 (es) |
| MA (1) | MA38273A1 (es) |
| MX (1) | MX2015008313A (es) |
| PH (1) | PH12015501071A1 (es) |
| SG (1) | SG11201503802UA (es) |
| TW (1) | TW201431559A (es) |
| WO (1) | WO2014108484A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9180185B2 (en) * | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| KR20170003572A (ko) | 2014-05-14 | 2017-01-09 | 에프. 호프만-라 로슈 아게 | Her3의 베타-헤어핀 및 her2의 도메인 ii에 결합하는 her3/her2 이중특이성 항체 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
| EP3570884B1 (en) | 2017-01-17 | 2020-09-30 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
| JP7181181B2 (ja) | 2017-02-28 | 2022-11-30 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法 |
| CN117180422A (zh) | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| HRP20230538T1 (hr) * | 2017-06-27 | 2023-08-04 | Regeneron Pharmaceuticals, Inc. | Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice |
| US11535669B2 (en) * | 2018-07-09 | 2022-12-27 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| US20220072144A1 (en) | 2018-09-20 | 2022-03-10 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
| WO2023031435A1 (en) * | 2021-09-03 | 2023-03-09 | Cancer Research Technology Limited | Treatment and prevention of cancer using her3 antigen-binding molecules |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| JP3925943B2 (ja) | 1996-03-27 | 2007-06-06 | ジェネンテック インコーポレーテッド | ＥｒｂＢ３抗体 |
| BR9709974A (pt) | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| EP1080113A4 (en) | 1998-05-15 | 2002-04-17 | Imclone Systems Inc | TREATMENT OF HUMAN TUMORS USING RADIATION AND GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS |
| EE200100118A (et) | 1998-08-27 | 2002-06-17 | Pfizer Products Inc. | Vähivastaste vahenditena kasulikud alkünüül-asendatud kinoliin-2-ooni derivaadid |
| EP1107962B1 (en) | 1998-08-27 | 2005-02-23 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| ID29584A (id) | 1999-02-11 | 2001-09-06 | Pfizer Prod Inc | Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| KR100797308B1 (ko) | 1999-06-25 | 2008-01-23 | 제넨테크, 인크. | 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE60008206T2 (de) | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| PL224786B1 (pl) | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
| JP2007500508A (ja) | 2003-07-29 | 2007-01-18 | モルフォテック、インク． | 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法 |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2005027966A2 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
| AU2005249492B2 (en) | 2004-05-27 | 2011-09-22 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| CN101048428A (zh) | 2004-09-08 | 2007-10-03 | 健泰科生物技术公司 | 利用死亡受体配体和cd20抗体的方法 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2006063042A2 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| AU2006211037B2 (en) * | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| EP2399605A1 (en) * | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| US20090215639A1 (en) | 2005-04-26 | 2009-08-27 | Bioren, Inc. | Method of Producing Human IgG Antibodies with Enhanced Effector Functions |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| NO345919B1 (no) | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2670522C (en) | 2006-11-28 | 2018-08-07 | U3 Pharma Gmbh | Activated her3 as a marker for predicting therapeutic efficacy |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2129396B1 (en) | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| PL2162149T3 (pl) | 2007-06-01 | 2014-04-30 | Henry M Jackson Found Advancement Military Medicine Inc | Szczepionka do zapobiegania nawrotowi raka sutka |
| US8529901B2 (en) | 2007-06-06 | 2013-09-10 | Hoffmann-La Roche, Inc. | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label |
| EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| PE20120015A1 (es) | 2008-08-15 | 2012-01-26 | Merrimack Pharmaceuticals Inc | Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico |
| WO2010052225A1 (en) | 2008-11-04 | 2010-05-14 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in normal her2 expressing settings |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
| CA2757531A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| BR112012003809A2 (pt) | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. |
| CA2775573A1 (en) | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
| EP2896632B1 (en) * | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| HUE029026T2 (en) * | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
| DK2536748T3 (da) | 2010-02-18 | 2014-10-13 | Genentech Inc | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft |
| PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
| SG184452A1 (en) | 2010-04-09 | 2012-11-29 | Aveo Pharmaceuticals Inc | Anti-erbb3 antibodies |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| PE20140230A1 (es) | 2010-08-20 | 2014-02-26 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| EP2621532A1 (en) | 2010-09-30 | 2013-08-07 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her3 antibodies |
| ES2632486T3 (es) | 2010-10-18 | 2017-09-13 | Mediapharma S.R.L. | Anticuerpo de unión a ErbB3 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| CA2816519C (en) | 2010-11-01 | 2019-01-15 | Symphogen A/S | Pan-her antibody composition |
| ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
| AU2012229062A1 (en) | 2011-03-15 | 2013-04-11 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to ErbB pathway inhibitors |
| PL2766040T3 (pl) | 2011-10-14 | 2019-11-29 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi |
| EP3608340A1 (en) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Binding molecules specific for her3 and uses thereof |
| UY34487A (es) * | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) |
| EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
| US8859797B1 (en) | 2012-04-27 | 2014-10-14 | Air Liquide Electronics U.S. Lp | Synthesis methods for carbosilanes |
| US9527913B2 (en) | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
| US9180185B2 (en) * | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
-
2014
- 2014-01-09 US US14/151,626 patent/US9180185B2/en active Active
- 2014-01-09 AR ARP140100081A patent/AR094403A1/es unknown
- 2014-01-10 WO PCT/EP2014/050344 patent/WO2014108484A2/en active Application Filing
- 2014-01-10 MA MA38273A patent/MA38273A1/fr unknown
- 2014-01-10 EA EA201500744A patent/EA201500744A1/ru unknown
- 2014-01-10 TW TW103101044A patent/TW201431559A/zh unknown
- 2014-01-10 EP EP14700281.0A patent/EP2943508B1/en active Active
- 2014-01-10 AU AU2014204795A patent/AU2014204795A1/en not_active Abandoned
- 2014-01-10 MX MX2015008313A patent/MX2015008313A/es unknown
- 2014-01-10 KR KR1020157018413A patent/KR20150093231A/ko not_active Application Discontinuation
- 2014-01-10 SG SG11201503802UA patent/SG11201503802UA/en unknown
- 2014-01-10 JP JP2015552051A patent/JP6257646B2/ja active Active
- 2014-01-10 CN CN201480003140.2A patent/CN104797602A/zh active Pending
- 2014-01-10 CA CA 2887508 patent/CA2887508A1/en not_active Abandoned
-
2015
- 2015-04-20 IL IL238393A patent/IL238393A0/en unknown
- 2015-04-23 CL CL2015001049A patent/CL2015001049A1/es unknown
- 2015-05-14 PH PH12015501071A patent/PH12015501071A1/en unknown
- 2015-05-28 CR CR20150284A patent/CR20150284A/es unknown
- 2015-10-07 US US14/877,569 patent/US20160159912A1/en not_active Abandoned
- 2015-12-24 HK HK15112676.9A patent/HK1211950A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1211950A1 (en) | 2016-06-03 |
| EP2943508B1 (en) | 2020-07-15 |
| MA38273A1 (fr) | 2017-05-31 |
| KR20150093231A (ko) | 2015-08-17 |
| CR20150284A (es) | 2015-06-30 |
| JP6257646B2 (ja) | 2018-01-10 |
| JP2016504399A (ja) | 2016-02-12 |
| SG11201503802UA (en) | 2015-08-28 |
| EA201500744A1 (ru) | 2015-12-30 |
| TW201431559A (zh) | 2014-08-16 |
| IL238393A0 (en) | 2015-06-30 |
| AR094403A1 (es) | 2015-07-29 |
| US20140227255A1 (en) | 2014-08-14 |
| WO2014108484A2 (en) | 2014-07-17 |
| AU2014204795A1 (en) | 2015-04-30 |
| PH12015501071A1 (en) | 2015-08-03 |
| CA2887508A1 (en) | 2014-07-17 |
| WO2014108484A3 (en) | 2014-09-04 |
| US9180185B2 (en) | 2015-11-10 |
| EP2943508A2 (en) | 2015-11-18 |
| US20160159912A1 (en) | 2016-06-09 |
| MX2015008313A (es) | 2015-11-11 |
| CN104797602A (zh) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001049A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
| DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
| DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
| DK2951203T3 (da) | Heterodimere proteiner | |
| CL2014000003S1 (es) | Automovil | |
| UA28362S (uk) | Автомобіль | |
| UA28570S (uk) | Автомобіль | |
| DK3041857T3 (da) | Protein a-kromatografi | |
| UA28733S (uk) | Автомобіль | |
| DK3068800T3 (da) | FcRn-specifikke antistoffer | |
| UA30094S (uk) | Автомобіль | |
| UA29168S (uk) | Автомобіль | |
| UA28738S (uk) | Автомобіль | |
| UA29027S (uk) | Автомобіль | |
| CL2014000346S1 (es) | Automovil | |
| CL2014000155S1 (es) | Automovil | |
| DK3065774T3 (da) | Anti-CCL17-antistoffer | |
| UA28962S (uk) | Автомобіль | |
| DK3080385T3 (da) | Forbedret lukkeapparat | |
| FI20136034A (fi) | Sauna | |
| UA27672S (uk) | Автомобіль | |
| CL2015002282S1 (es) | Encendedor | |
| UA28711S (uk) | Масажер | |
| CL2014001240S1 (es) | Automovil | |
| CL2014000437S1 (es) | Automovil |